Article
Treatment patterns and outcomes in KRASG12C-positive advanced NSCLC patients previously treated with immune checkpoint inhibitors: A Canada-wide real-world, multi-center, retrospective cohort study.
Lung cancer (Amsterdam, Netherlands) - 1 Aug 2024
Barghout Samir H, Zhan Luna Jia, Raptis Starvroula, Al-Agha Faisal, Esfahanian Niki, Popovacki Aimee, Kasymjanova Goulnar, Proulx-Rocray Francis, Chan Sze Wah Samuel, Richardson Matthew, Brown M Catherine, Patel Devalben, Dean Michelle Liane, Navani Vishal, Moore Erica, Carvery Lane, Yan Elizabeth, Goldshtein Daniel, Cleary-Gosine Jasmine, Gibson Amanda Jw, Hubley Lynn, Balaratnam Karmugi, Ngo Tran, Gill Azee, Black Morgan, Sacher Adrian, Bradbury Penelope A, Shepherd Frances A, Leighl Natasha, Cheema Parneet, Kuruvilla Sara, Agulnik Jason, Banerji Shantanu, Juergens Rosalyn, Blais Normand, Cheung Winson, Wheatley-Price Paul, Liu Geoffrey, Snow Stephanie
Abstract excerpt
OBJECTIVES: KRAS mutations, particularly KRASG12C, are prevalent in non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors (ICIs) have been a frontline treatment, but recently developed KRASG12C-selective inhibitors, such as sotorasib, present new therapeutic options. We conducted a multi-center retrospective cohort study to gain insights into real-world treatment patterns and outcomes in patients with...
Topics
Join the communities discussing this publication.